Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids
NCT03616184
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
49
Enrollment
OTHER
Sponsor class
Conditions
Graft-versus-host-disease (GVHD)
Interventions
DRUG:
Ruxolitinib
Sponsor
University of Nebraska